Forlong Biotechnology: RMB 120 Million Series Pre-B Financing Raised To Advance Cytokine Therapy Pipeline
By Amit Chowdhry ● May 19, 2026
Forlong Biotechnology, a clinical-stage biotech company focused on developing cytokine therapies for patients with severe unmet medical needs, announced the completion of an RMB 120 million, approximately $17.5 million, Series Pre-B financing round. The round was co-led by an undisclosed fund and Fudan Capital, with participation from Changshu Guofa Venture, Kunsheng Relay Fund, and other investors.